MetaVia Inc.

NasdaqCM:MTVA Stock Report

Market Cap: US$6.2m

MetaVia Dividends and Buybacks

Dividend criteria checks 0/6

MetaVia does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-180.8%

Buyback Yield

Total Shareholder Yield-180.8%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Analysis Article • Sep 17

We're Keeping An Eye On MetaVia's (NASDAQ:MTVA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 03

Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Sep 29

NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

NeuroBo Pharmaceuticals (NASDAQ:NRBO) received Nasdaq notification indicating that the company has evidenced full compliance with the minimum bid price requirement As a result, the listing matter has been closed. Shares are trading up 4% premarket.
Analysis Article • Sep 14

Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Sep 12

NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split

NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares are surging 56% on announcing a 1-for-30 reverse split of its common stock, par value $0.001.  The trading on a split adjusted basis will commence on Nasdaq from September 13, 2022. The number of authorized shares of the company's common stock will remain at 100M, while the number of outstanding shares will be reduced from ~26.7M to ~0.9M.
Seeking Alpha • Nov 25

NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases

NeuroBo Pharmaceuticals is advancing novel disease-modifying therapies for viral, neuropathic and neurodegenerative diseases. The Company has four candidates in the development pipeline, with the lead candidate ANA001 being advanced for treatment of moderate COVID-19. The Company seeks an EUA for the lead candidate, failing which it intends to pursue an NDA via a 505(b)(2) pathway.
Analysis Article • Dec 21

Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like

If you want to know who really controls NeuroBo Pharmaceuticals, Inc. ( NASDAQ:NRBO ), then you'll have to look at the...

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if MTVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MTVA's dividend payments have been increasing.

Dividend Yield vs Market

MetaVia Dividend Yield vs Market
How does MTVA dividend yield compare to the market?
SegmentDividend Yield
Company (MTVA)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.3%
Industry Average (Biotechs)2.4%
Analyst forecast (MTVA) (up to 3 years)n/a

Notable Dividend: Unable to evaluate MTVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MTVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate MTVA's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MTVA has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/14 05:52
End of Day Share Price 2026/05/14 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MetaVia Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew FeinH.C. Wainwright & Co.
Jason McCarthyMaxim Group
David BautzZacks Small-Cap Research